Reversal of Neuromuscular Blockade
2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Hanlim PharmKorea - Seoul
1 programEvaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled InjectionN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MSDSugammadex 2 mg/kg
Hanlim PharmEvaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection
Clinical Trials (2)
Total enrollment: 1,844 patients across 2 trials
Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)
Start: Dec 2017Est. completion: Sep 2019344 patients
Phase 4Completed
NCT06246331Hanlim PharmEvaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection
Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection
Start: Jul 2023Est. completion: Dec 20241,500 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.